Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
The first studies, launched on July 31, will focus on viral persistence and cognitive dysfunction.
Several mechanisms may play a role, including persistent virus and ongoing immune dysregulation.
The condition may be caused by hidden viral reservoirs that remain in the body after initial infection.
People without insurance will need to either pay full price, seek free or low-cost vaccines from community clinics or go without.
Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.
Before they get COVID, people over 65 should have a plan for accessing antiviral treatment.
The antiviral treatment reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.
Get a COVID booster, especially if you’re older or your immune system is compromised, and don’t forget the flu shot.
Safety tips for the evolving pandemic. Plus: Which groups—such as those with cancer or HIV—are at higher risk for COVID-19 complications?
The small study found no evidence of delayed development of antibodies in participants who experienced rebound after taking Paxlovid.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.